Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Alzheimer's Research & Therapy
Published in: Alzheimer's Research & Therapy 1/2019

Open Access 01-12-2019 | Alzheimer's Disease | Research

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Authors: Simon Sjödin, Gunnar Brinkmalm, Annika Öhrfelt, Lucilla Parnetti, Silvia Paciotti, Oskar Hansson, John Hardy, Kaj Blennow, Henrik Zetterberg, Ann Brinkmalm

Published in: Alzheimer's Research & Therapy | Issue 1/2019

Login to get access

Abstract

Background

Increasing evidence implicates dysfunctional proteostasis and the involvement of the autophagic and endo-lysosomal system and the ubiquitin-proteasome system in neurodegenerative diseases. In Alzheimer’s disease (AD), there is an accumulation of autophagic vacuoles within the neurons. In Parkinson’s disease (PD), susceptibility has been linked to genes encoding proteins involved in autophagy and lysosomal function, as well as mutations causing lysosomal disorders. Furthermore, both diseases are characterized by the accumulation of protein aggregates.

Methods

Proteins associated with endocytosis, lysosomal function, and the ubiquitin-proteasome system were identified in the cerebrospinal fluid (CSF) and targeted by combining solid-phase extraction and parallel reaction monitoring mass spectrometry. In total, 50 peptides from 18 proteins were quantified in three cross-sectional cohorts including AD (N = 61), PD (N = 21), prodromal AD (N = 10), stable mild cognitive impairment (N = 15), and controls (N = 68).

Results

A pilot study, including subjects selected based on their AD CSF core biomarker concentrations, showed increased concentrations of several targeted proteins in subjects with core biomarker levels indicating AD pathology compared to controls. Next, in a clinically characterized cohort, lower concentrations in CSF of proteins in PD were found compared to subjects with prodromal AD. Further investigation in an additional clinical study again revealed lower concentrations in CSF of proteins in PD compared to controls and AD.

Conclusion

In summary, significantly different peptide CSF concentrations were identified from proteins AP2B1, C9, CTSB, CTSF, GM2A, LAMP1, LAMP2, TCN2, and ubiquitin. Proteins found to have altered concentrations in more than one study were AP2B1, CTSB, CTSF, GM2A, LAMP2, and ubiquitin. Interestingly, given the genetic implication of lysosomal function in PD, we did identify the CSF concentrations of CTSB, CTSF, GM2A, and LAMP2 to be altered. However, we also found differences in proteins associated with endocytosis (AP2B1) and the ubiquitin-proteasome system (ubiquitin). No difference in any peptide CSF concentration was found in clinically characterized subjects with AD compared to controls. In conclusion, CSF analyses of subjects with PD suggest a general lysosomal dysfunction, which resonates well with recent genetic findings, while such changes are minor or absent in AD.
Appendix
Available only for authorised users
Literature
1.
Alzheimer’s Association. 2017 Alzheimer’s disease facts and figures. Alzheimers Dement. 2017;13(4):325–73.CrossRef
2.
3.
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82(12):4245–9.PubMedPubMedCentralCrossRef
4.
Wood JG, Mirra SS, Pollock NJ, Binder LI. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci U S A. 1986;83(11):4040–3.PubMedPubMedCentralCrossRef
5.
Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A. 1986;83(11):4044–8.PubMedPubMedCentralCrossRef
6.
Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83(13):4913–7.PubMedPubMedCentralCrossRef
7.
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40.PubMedCrossRef
8.
Dehay B, Martinez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, et al. Lysosomal impairment in Parkinson's disease. Mov Disord. 2013;28(6):725–32.PubMedPubMedCentralCrossRef
9.
Whyte LS, Lau AA, Hemsley KM, Hopwood JJ, Sargeant TJ. Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer’s disease? J Neurochem. 2017;140(5):703–17.PubMedCrossRef
10.
11.
Yamamoto A, Yue Z. Autophagy and its normal and pathogenic states in the brain. Annu Rev Neurosci. 2014;37:55–78.PubMedCrossRef
12.
13.
Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer’s disease and Down syndrome. Am J Pathol. 2000;157(1):277–86.PubMedPubMedCentralCrossRef
14.
Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci. 1997;17(16):6142–51.PubMedCrossRefPubMedCentral
15.
Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005;64(2):113–22.PubMedCrossRef
16.
Anglade P. Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease. Histol Histopathol. 1997;12(1):25–31.PubMed
17.
Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, et al. Pathogenic lysosomal depletion in Parkinson’s disease. J Neurosci. 2010;30(37):12535–44.PubMedPubMedCentralCrossRef
18.
Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol. 2010;67(12):1464–72.PubMedCrossRef
19.
Murphy KE, Gysbers AM, Abbott SK, Spiro AS, Furuta A, Cooper A, et al. Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. Mov Disord. 2015;30(12):1639–47.PubMedCrossRef
20.
Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009;35(3):385–98.PubMedCrossRef
21.
Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med. 2004;351(19):1972–7.PubMedCrossRef
22.
Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361(17):1651–61.PubMedPubMedCentralCrossRef
23.
Sidransky E. Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab. 2004;83(1):6–15.PubMedCrossRef
24.
Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease. Brain. 2017;140:3191–203.PubMedPubMedCentralCrossRef
25.
Gao S, Casey AE, Sargeant TJ, Mäkinen V-P. Genetic variation within endolysosomal system is associated with late-onset Alzheimer’s disease. Brain. 2018;141:2711–20.PubMedCrossRef
26.
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41(10):1088–93.PubMedPubMedCentralCrossRef
27.
Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131–44.PubMedCrossRef
28.
Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84.PubMedCrossRef
29.
Armstrong A, Mattsson N, Appelqvist H, Janefjord C, Sandin L, Agholme L, et al. Lysosomal network proteins as potential novel CSF biomarkers for Alzheimer's disease. NeuroMolecular Med. 2014;16(1):150–60.PubMedCrossRef
30.
Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener. 2015;10:64.PubMedPubMedCentralCrossRef
31.
Sjödin S, Öhrfelt A, Brinkmalm G, Zetterberg H, Blennow K, Brinkmalm A. Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. Clin Proteomics. 2016;13(1):4.PubMedPubMedCentralCrossRef
32.
Wang GP, Iqbal K, Bucht G, Winblad B, Wisniewski HM, Grundke-Iqbal I. Alzheimer’s disease: paired helical filament immunoreactivity in cerebrospinal fluid. Acta Neuropathol. 1991;82(1):6–12.PubMedCrossRef
33.
Blennow K, Davidsson P, Wallin A, Gottfries CG, Svennerholm L. Ubiquitin in cerebrospinal fluid in Alzheimer’s disease and vascular dementia. Int Psychogeriatr. 1994;6(1):13–22.PubMedCrossRef
34.
Oeckl P, Steinacker P, von Arnim CA, Straub S, Nagl M, Feneberg E, et al. Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration. J Proteome Res. 2014;13(11):4518–25.PubMedCrossRef
35.
Sjödin S, Hansson O, Öhrfelt A, Brinkmalm G, Zetterberg H, Brinkmalm A, et al. Mass spectrometric analysis of cerebrospinal fluid ubiquitin in Alzheimer's disease and parkinsonian disorders. Proteomics Clin Appl. 2017;11(11–12):1700100.PubMedCentralCrossRef
36.
Parnetti L, Cicognola C, Eusebi P, Chiasserini D. Value of cerebrospinal fluid alpha-synuclein species as biomarker in Parkinson’s diagnosis and prognosis. Biomark Med. 2016;10(1):35–49.PubMedCrossRef
37.
Balducci C, Pierguidi L, Persichetti E, Parnetti L, Sbaragli M, Tassi C, et al. Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson’s disease. Mov Disord. 2007;22(10):1481–4.PubMedCrossRef
38.
Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord. 2014;29(8):1019–27.PubMedCrossRef
39.
Parnetti L, Paciotti S, Eusebi P, Dardis A, Zampieri S, Chiasserini D, et al. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients. Mov Disord. 2017;32(10):1423–31.PubMedCrossRef
40.
Boman A, Svensson S, Boxer A, Rojas JC, Seeley WW, Karydas A, et al. Distinct lysosomal network protein profiles in parkinsonian syndrome cerebrospinal fluid. J Park Dis. 2016;6(2):307–15.
41.
Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86(11):1240–7.PubMedCrossRef
42.
Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012;69(11):1445–52.PubMedCrossRef
43.
Brinkmalm G, Sjödin S, Simonsen AH, Hasselbalch SG, Zetterberg H, Brinkmalm A, et al. A parallel reaction monitoring mass spectrometric method for analysis of potential CSF biomarkers for Alzheimer's disease. Proteomics Clin Appl. 2018;12(1):1700131.CrossRef
44.
Peterson AC, Russell JD, Bailey DJ, Westphall MS, Coon JJ. Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics. 2012;11(11):1475–88.PubMedPubMedCentralCrossRef
45.
Gallien S, Duriez E, Demeure K, Domon B. Selectivity of LC-MS/MS analysis: implication for proteomics experiments. J Proteome. 2013;81:148–58.CrossRef
46.
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29.PubMedCrossRef
47.
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270–9.PubMedPubMedCentralCrossRef
48.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.PubMedPubMedCentralCrossRef
49.
Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33–9.PubMedCrossRef
50.
51.
52.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34(7):939–44.PubMedCrossRef
53.
Hall S, Surova Y, Öhrfelt A, Blennow K, Zetterberg H, Hansson O. Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease. Mov Disord. 2016;31(6):898–905.PubMedPubMedCentralCrossRef
54.
Chiasserini D, Biscetti L, Farotti L, Eusebi P, Salvadori N, Lisetti V, et al. Performance evaluation of an automated ELISA system for Alzheimer’s disease detection in clinical routine. J Alzheimers Dis. 2016;54(1):55–67.PubMedCrossRef
55.
McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2011;12(8):517–33.PubMedCrossRef
56.
57.
58.
59.
Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta. 2012;1824(1):68–88.PubMedCrossRef
60.
Zaidi N, Maurer A, Nieke S, Kalbacher H. Cathepsin D: A cellular roadmap. Biochem Biophys Res Commun. 2008;376(1):5–9.PubMedCrossRef
61.
Maes M-B, Scharpé S, De Meester I. Dipeptidyl peptidase II (DPPII), a review. Clin Chim Acta. 2007;380(1):31–49.PubMedCrossRef
62.
63.
Lemieux MJ, Mark BL, Cherney MM, Withers SG, Mahuran DJ, James MNG. Crystallographic structure of human β-Hexosaminidase a: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis. J Mol Biol. 2006;359(4):913–29.PubMedPubMedCentralCrossRef
64.
Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P, Grinstein S. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 2007;26(2):313–24.PubMedPubMedCentralCrossRef
65.
Saftig P, Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat Rev Mol Cell Biol. 2009;10(9):623–35.PubMedCrossRef
66.
67.
68.
Gherasim C, Lofgren M, Banerjee R. Navigating the B (12) road: assimilation, delivery, and disorders of cobalamin. J Biol Chem. 2013;288(19):13186–93.PubMedPubMedCentralCrossRef
69.
70.
71.
de Graaf EL, Altelaar AF, van Breukelen B, Mohammed S, Heck AJ. Improving SRM assay development: a global comparison between triple quadrupole, ion trap, and higher energy CID peptide fragmentation spectra. J Proteome Res. 2011;10(9):4334–41.PubMedCrossRef
72.
International Organization for Standardization. Accuracy (trueness and precision) of measurement methods and results — Part 2: Basic method for the determination of repeatability and reproducibility of a standard measurement method (Standard 5725-2:1994). International Organization for Standardization; 1994. Retrieved from https://​www.​iso.​org/​standard/​11834.​html.
73.
MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26(7):966–8.PubMedPubMedCentralCrossRef
74.
Duits FH, Brinkmalm G, Teunissen CE, Brinkmalm A, Scheltens P, Van der Flier WM, et al. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2018;10(1):5.PubMedPubMedCentralCrossRef
75.
Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol. 2012;72(3):455–63.PubMedPubMedCentralCrossRef
76.
Chiasserini D, Paciotti S, Eusebi P, Persichetti E, Tasegian A, Kurzawa-Akanbi M, et al. Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies. Mol Neurodegener. 2015;10:15.PubMedPubMedCentralCrossRef
77.
van Dijk KD, Persichetti E, Chiasserini D, Eusebi P, Beccari T, Calabresi P, et al. Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. Mov Disord. 2013;28(6):747–54.PubMedCrossRef
78.
Parnetti L, Balducci C, Pierguidi L, De Carlo C, Peducci M, D'Amore C, et al. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in dementia with Lewy bodies. Neurobiol Dis. 2009;34(3):484–6.PubMedCrossRef
79.
Gough NR, Hatem CL, Fambrough DM. The family of LAMP-2 proteins arises by alternative splicing from a single gene: characterization of the avian LAMP-2 gene and identification of mammalian homologs of LAMP-2b and LAMP-2c. DNA Cell Biol. 1995;14(10):863–7.PubMedCrossRef
80.
81.
Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science. 1996;273(5274):501–3.PubMedCrossRef
82.
Cuervo AM, Dice JF. Age-related decline in chaperone-mediated autophagy. J Biol Chem. 2000;275(40):31505–13.PubMedCrossRef
83.
Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305(5688):1292–5.PubMedCrossRef
84.
Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem. 2008;283(35):23542–56.PubMedPubMedCentralCrossRef
85.
Constantinescu R, Andreasson U, Li S, Podust VN, Mattsson N, Anckarsäter R, et al. Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. Parkinsonism Relat Disord. 2010;16(8):545–9.PubMedCrossRef
86.
Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. Lewy bodies are ubiquitinated - a light and electron microscopic immunocytochemical study. Acta Neuropathol. 1988;75(4):345–53.PubMedCrossRef
87.
Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, et al. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem. 2002;277(50):49071–6.PubMedCrossRef
88.
89.
Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer’s disease. Neurobiol Aging. 1997;18(4):415–21.PubMedCrossRef
90.
Shen Y, Li R, McGeer EG, McGeer PL. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997;769(2):391–5.PubMedCrossRef
91.
Cataldo AM, Hamilton DJ, Nixon RA. Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. Brain Res. 1994;640(1–2):68–80.PubMedCrossRef
92.
Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn S, et al. Gene expression and cellular content of cathepsin D in Alzheimer’s disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron. 1995;14(3):671–80.PubMedCrossRef
93.
Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y, et al. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol Psychiatry. 2010;68(10):885–93.PubMedPubMedCentralCrossRef
94.
Ginsberg SD, Mufson EJ, Alldred MJ, Counts SE, Wuu J, Nixon RA, et al. Upregulation of select Rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. J Chem Neuroanat. 2011;42(2):102–10.PubMedPubMedCentralCrossRef
95.
Musunuri S, Wetterhall M, Ingelsson M, Lannfelt L, Artemenko K, Bergquist J, et al. Quantification of the brain proteome in Alzheimer’s disease using multiplexed mass spectrometry. J Proteome Res. 2014;13(4):2056–68.PubMedCrossRef
96.
Cataldo AM, Nixon RA. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc Natl Acad Sci U S A. 1990;87(10):3861–5.PubMedPubMedCentralCrossRef
97.
Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, et al. Higher cathepsin B levels in plasma in Alzheimer’s disease compared to healthy controls. J Alzheimers Dis. 2010;22(4):1223–30.PubMedCrossRef
98.
Manaka H, Kato T, Kurita K, Katagiri T, Shikama Y, Kujirai K, et al. Marked increase in cerebrospinal fluid ubiquitin in Creutzfeldt-Jakob disease. Neurosci Lett. 1992;139(1):47–9.PubMedCrossRef
99.
Steinacker P, Rist W, Swiatek-de-Lange M, Lehnert S, Jesse S, Pabst A, et al. Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease. Proteomics. 2010;10(1):81–9.PubMedCrossRef
100.
Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, Davies HA, et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol. 2007;64(3):366–70.PubMedCrossRef
101.
Hagihara M, Mihara R, Togari A, Nagatsu T. Dipeptidyl-aminopeptidase II in human cerebrospinal fluid: changes in patients with Parkinson’s disease. Biochem Med Metab Biol. 1987;37(3):360–5.PubMedCrossRef
102.
Mantle D, Falkous G, Ishiura S, Perry RH, Perry EK. Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer’s disease, Lewy body dementia, Parkinson's disease and Huntington’s disease. J Neurol Sci. 1995;131(1):65–70.PubMedCrossRef
103.
Helmfors L, Boman A, Civitelli L, Nath S, Sandin L, Janefjord C, et al. Protective properties of lysozyme on β-amyloid pathology: implications for Alzheimer disease. Neurobiol Dis. 2015;83:122–33.PubMedCrossRef
104.
Sandin L, Bergkvist L, Nath S, Kielkopf C, Janefjord C, Helmfors L, et al. Beneficial effects of increased lysozyme levels in Alzheimer’s disease modelled in Drosophila melanogaster. FEBS J. 2016;283(19):3508–22.PubMedPubMedCentralCrossRef
105.
Cragg H, Williamson M, Young E, O'Brien J, Alhadeff J, Fang-Kircher S, et al. Fucosidosis: genetic and biochemical analysis of eight cases. J Med Genet. 1997;34(2):105–10.PubMedPubMedCentralCrossRef
106.
107.
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3.PubMedCrossRef
108.
He X, Cooley K, Chung CHY, Dashti N, Tang J. Apolipoprotein receptor 2 and X11α/β mediate apolipoprotein E-induced endocytosis of amyloid-β precursor protein and β-secretase, leading to amyloid-β production. J Neurosci. 2007;27(15):4052–60.PubMedPubMedCentralCrossRef
109.
Ji Z-S, Miranda RD, Newhouse YM, Weisgraber KH, Huang Y, Mahley RW. Apolipoprotein E4 potentiates amyloid β peptide-induced lysosomal leakage and apoptosis in neuronal cells. J Biol Chem. 2002;277(24):21821–8.PubMedCrossRef
110.
Hansson KT, Skillbäck T, Pernevik E, Kern S, Portelius E, Höglund K, et al. Expanding the cerebrospinal fluid endopeptidome. Proteomics. 2017;17(5):1600384.CrossRef
111.
Mori H, Kondo J, Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science. 1987;235(4796):1641–4.PubMedCrossRef
112.
Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A. 1987;84(9):3033–6.PubMedPubMedCentralCrossRef
113.
Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain. 2006;129(Pt 11):3035–41.PubMedCrossRef
114.
Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, et al. Cerebrospinal fluid markers for Alzheimer’s disease evaluated after acute ischemic stroke. J Alzheimers Dis. 2000;2(3–4):199–206.PubMedCrossRef
115.
Rodríguez A, Webster P, Ortego J, Andrews NW. Lysosomes behave as Ca2+-regulated Exocytic vesicles in fibroblasts and epithelial cells. J Cell Biol. 1997;137(1):93–104.PubMedPubMedCentralCrossRef
116.
Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS, et al. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med. 2012;10(1):5.PubMedPubMedCentralCrossRef
117.
Reddy A, Caler EV, Andrews NW. Plasma membrane repair is mediated by Ca2+−regulated exocytosis of lysosomes. Cell. 2001;106(2):157–69.PubMedCrossRef
118.
Chen G, Zhang Z, Wei Z, Cheng Q, Li X, Li W, et al. Lysosomal exocytosis in Schwann cells contributes to axon remyelination. Glia. 2012;60(2):295–305.PubMedCrossRef
119.
Arantes RME, Andrews NW. A role for Synaptotagmin VII-regulated exocytosis of lysosomes in neurite outgrowth from primary sympathetic neurons. J Neurosci. 2006;26(17):4630–7.PubMedPubMedCentralCrossRef
120.
Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, Purvine SO, et al. Establishing the Proteome of Normal Human Cerebrospinal Fluid. PLoS One. 2010;5(6):e10980.PubMedPubMedCentralCrossRef
121.
Guldbrandsen A, Vethe H, Farag Y, Oveland E, Garberg H, Berle M, et al. In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). Mol Cell Proteomics. 2014;13(11):3152–63.PubMedPubMedCentralCrossRef
122.
Hladky SB, Barrand MA. Mechanisms of fluid movement into, through and out of the brain: Evaluation of the evidence. Fluids Barriers CNS. 2014;11(1):26.PubMedPubMedCentralCrossRef
123.
Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457–70.PubMedPubMedCentralCrossRef
124.
Chiasserini D, van Weering JRT, Piersma SR, Pham TV, Malekzadeh A, Teunissen CE, et al. Proteomic analysis of cerebrospinal fluid extracellular vesicles: A comprehensive dataset. J Proteomics. 2014;106(Supplement C):191–204.PubMedCrossRef
125.
Goetzl EJ, Boxer A, Schwartz JB, Abner EL, Petersen RC, Miller BL, et al. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology. 2015;85(1):40–7.PubMedPubMedCentralCrossRef
126.
Vizcaíno JA, Côté RG, Csordas A, Dianes JA, Fabregat A, Foster JM, et al. The proteomics identifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2012;41(D1):D1063–D9.PubMedPubMedCentralCrossRef
127.
Sharma V, Eckels J, Schilling B, Ludwig C, Jaffe JD, MacCoss MJ, et al. Panorama public: a public repository for quantitative data sets processed in skyline. Mol Cell Proteomics. 2018;17(6):1239–44.PubMedPubMedCentralCrossRef
Metadata
Title
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Authors
Simon Sjödin
Gunnar Brinkmalm
Annika Öhrfelt
Lucilla Parnetti
Silvia Paciotti
Oskar Hansson
John Hardy
Kaj Blennow
Henrik Zetterberg
Ann Brinkmalm
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 1/2019
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/s13195-019-0533-9

Other articles of this Issue 1/2019

Alzheimer's Research & Therapy 1/2019 Go to the issue

Research

Data-driven prognostic features of cognitive trajectories in patients with amnestic mild cognitive impairments

Research

Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers

Research

Sleep experiences during different lifetime periods and in vivo Alzheimer pathologies

Review

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Research

Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial

Research

Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: impact on diagnostic confidence and diagnostic accuracy